| |
Roche HCV Drug R1626 Terminated
|
| |
| |
This was part of Roche earnings report over the internet today:
"Development of R1626, a polymerase inhibitor being investigated as a treatment for infection with hepatitis C virus (HCV), was terminated in the third quarter due to new and unexpected safety findings from a phase IIb study. Roche?s pipeline of direct antiviral agents for HCV remains robust, with another polymerase inhibitor, R7128 (collaboration with Pharmasset), and a protease inhibitor, R7227 (collaboration with InterMune) in clinical development. Both agents are being investigated in combination with Pegasys and Copegus (ribavirin)."
|
|
| |
| |
|
|
|
